Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2022 | Management of newly diagnosed patients with multiple myeloma not eligible for transplantation

Maximilian Merz • 24 Mar 2022
EBMT 2022
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide Melphalan Prednisone
ALCYONE MAIA

Maximilian Merz, MD, Leipzig University, Leipzig, Germany, Roswell Park Comprehensive Center Institute, Buffalo, NY, comments on the management of patients with multiple myeloma not eligible for transplant, where a paradigm shift has been observed after the introduction of CD38 antibodies to upfront therapy, with higher rates of progression-free survival (PFS) and overall survival (OS) and long-lasting remissions. Data from the ALCYONE (NCT02195479) and MAIA (NCT02252172) trials led to the approval of several combinations of daratumumab, with a notable outcome improvement in elderly and frail patients. Dr Merz considers that the standard of care should point to antibody plus lenalidomide-dexamethasone (Rd) or bortezomib-melphalan-prednisone (VMP), but more data on quadruplet therapy for ineligible patients is needed. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Disclosures

Advisory board: Janssen, BMS/Celgene, Amgen, GSK, Sanofi
Consultancy: onkowissen.de, Hexal, oncologyinformationservice
Travel support: Amgen, BMS/Celgene, Janssen, Abbvie, Takeda
Research support: Takeda, BMS/Celgene

More from Maximilian Merz

Factors to consider when manufacturing CAR T-cells for patients with R/R multiple myeloma 1:50
Factors to consider when manufacturing CAR T-cells for patients with R/R multiple myeloma
Maximilian Merz • 10 Dec 2023
CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM 1:34
CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM
Maximilian Merz • 10 Dec 2023
Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM 1:52
Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM
Maximilian Merz • 10 Dec 2023
Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort 2:08
Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort
Maximilian Merz • 24 Mar 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals